Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
As the data collection was split between two different days, the data was split into 18 optics groups
NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
Mounjaro has not yet received these indications, although studies are ongoing
npj Metab Health Dis 3 , 36 (2025)
Acta Biochim Biophys Sin
researchers building on or replicating that work need the same tool Cardiac and cytoprotective studies: Ischemia-reperfusion injury models have accumulated preclinical evidence for GHRP-6-mediated cardioprotection potentially through GHSR-1a pathways in cardiomyocytes and inflammatory modulation CNS/reward circuitry: GHSR-1a forms heterodimers with dopamine D1 receptors
US$ 27.36
US$ 23.59
US$ 26.53
US$ 23.52
